

## Drug Injury Watch: Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti

(Posted by Tom Lamb at [www.DrugInjuryWatch.com](http://www.DrugInjuryWatch.com) on March 14, 2017)

Invokana (canagliflozin) was approved by the FDA in 2013. Invokamet (canagliflozin and metformin) was approved by the FDA in 2014. Both of these drugs were approved for use by patients with Type 2 diabetes.

In December 2015 the FDA issued this Drug Safety Communication: "FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections". In part, it warned about the risk of ketoacidosis, a serious medical condition caused by having too much acid in the blood, for Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, a class of newer diabetes drugs which include Invokana and Invokamet.

In May and June 2016 the FDA announced it had strengthened the existing warning about the risk of acute kidney injury for Invokana and Invokamet.

In August 2016 the FDA sent letters to Janssen for Invokana and Invokamet label changes concerning fatal cases of ketoacidosis.

Due in part to these FDA drug safety alerts, there have been lawsuits filed on behalf of diabetes patients who used Invokana or Invokamet. Those lawsuits recently gave rise to a request for the consolidation of all Invokana and Invokamet cases pending in the various federal court districts around the country before one judge.

In September 2016, pursuant to 28 U.S.C. § 1407, a motion was filed to establish IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION, MDL Docket No. 2750.

In October 2016 the attorneys for Defendant Janssen Pharmaceuticals, Inc. ("Janssen") indicated, in their legal document filed as a response to this MDL motion, it agreed that all Invokana cases filed in the federal court system should be consolidated. Further, they agreed that federal Judge Brian Martinotti, of the District of New Jersey, would be an appropriate choice by the Judicial Panel for Multidistrict Litigation (JPML) for the so-called "transferee judge" presiding over this Invokana MDL.

In December 2016 the JPML issued an Order establishing this consolidation of all Invokana and Invokamet federal court lawsuits.

We are currently investigating possible Invokamet and Invokana lawsuits against the drug company Janssen for diabetes patients who have developed any of the medical conditions listed above.

Of course, we will continue to monitor the Invokana / Invokamet legal cases and report significant developments here.

[\[Read this article in full at original source\]](#)

***Earlier Invokana / Farxiga / Jardiance articles by attorney Tom Lamb on the [Side Effects Blog](#):***

- [New Federal Court Multidistrict Litigation \(MDL\) For Farxiga Lawsuits](#)
- [Invokana Has New Warning About Risk Of Lower Limb Amputation In Canada](#)

- [December 2016: FDA Requires Safety Warnings Label Change For Jardiance](#)
- [Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning](#)
- [Invokana / Farxiga / Jardiance: UTIs Then Urosepsis And Pyelonephritis](#)

---

Attorney [Tom Lamb](#) represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.  
<http://www.DrugInjuryWatch.com>